DealBio
All collections

Investor Intelligence

13 Oncology Investors in Europe

European investors with demonstrated activity across oncology therapeutics, cancer immunotherapy, precision medicine and cancer-focused biotechnology.

Published
  • Oncology
  • Cancer Immunotherapy
  • Biotechnology
  • Precision Medicine
  • Europe
  • Seed
  • Series A

financing in Europe spans specialist life-sciences funds, company-creation investors, translational research capital and early-stage venture firms. The strongest precedents range from cancer vaccines and antibody therapeutics to cell therapies and precision oncology, reflecting the breadth of technologies being financed across the sector.

DealBio selected 13 investors with evidenced relevance to oncology in Europe, using current investor research, financing precedents and public verification where needed.

Andera Partners

European private-markets investor with a dedicated life-sciences strategy backing biotechnology and healthcare companies.

Stage
Seed · Series A · Growth
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Belgium · Europe
Investor type
VC

Relevant investment

Andera Partners co-led Adcytherix’s €105 million Series A in October 2025. Adcytherix develops antibody-drug conjugates with novel payloads for cancer, giving Andera a direct European oncology precedent in targeted therapeutics.

V-Bio Ventures

Belgian life-sciences VC investing in early-stage therapeutics and biotechnology companies.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Europe
Investor type
VC

Relevant investment

V-Bio Ventures led Flindr Therapeutics’ €20 million Series A in April 2024. Flindr develops first-in-class small-molecule medicines for precision oncology and uses biomarkers to identify patient populations most likely to respond.

Samsara BioCapital

Biotechnology-focused investment firm partnering with companies developing new medicines.

Stage
Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Sweden · United Kingdom · Europe
Investor type
VC

Relevant investment

Samsara BioCapital co-led Ottimo Pharma’s Series A of more than $140 million in December 2024. Ottimo is developing a PD-1/VEGFR2 bifunctional antibody for multiple solid-tumour indications, giving Samsara a direct large-scale oncology financing precedent.

Sound Bioventures

Transatlantic life-sciences VC investing in clinical-stage biotherapeutics companies.

Stage
Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
France · Belgium · Spain
Investor type
VC

Relevant investment

Sound Bioventures participated in Cytospire Therapeutics’ £61 million Series A in May 2026. Cytospire is developing multispecific gamma-delta T-cell engager antibodies for solid and blood cancers, giving Sound a direct next-generation cancer-immunotherapy precedent.

AdBio Partners

European VC focused on company creation and early-stage biotechnology.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
France · Europe
Investor type
VC

Relevant investment

AdBio Partners backed Integra Therapeutics from its €4.5 million initial financing and continued into the company’s €10.7 million 2025 round. Integra is developing gene-writing technology and CAR-T programmes, giving AdBio direct exposure to advanced cancer therapies.

Angels Santé

French angel network focused on healthcare, life sciences and medical innovation.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
France · Belgium
Investor type
VC

Relevant investment

Angels Santé participated in HEPHAISTOS-Pharma’s financing, including a €4.5 million seed round within €10.3 million of total funding. HEPHAISTOS develops next-generation cancer immunotherapies that activate innate immunity, providing a direct early-stage oncology precedent.

WE International

European healthcare investor backing biotechnology and therapeutics companies.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
United Kingdom
Investor type
VC

Relevant investment

WE International backed ATB Therapeutics, a Belgian biotechnology company developing targeted antibody therapies for cancer and autoimmune disease. ATB combines recombinant antibodies, linkers and payloads to selectively deliver therapeutic activity to diseased cells.

SIS Ventures

UK impact investor backing science-led companies including life sciences and drug discovery.

Stage
Seed
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
United Kingdom
Investor type
VC

Relevant investment

SIS Ventures participated in Carcinotech’s £1.6 million financing. Carcinotech manufactures 3D-printed patient-derived tumour models for personalised drug testing and preclinical oncology research, giving SIS a direct cancer-technology precedent.

Forbion

European life-sciences VC investing across biotechnology from company formation through growth.

Stage
Series A · Growth
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Europe
Investor type
VC

Relevant investment

Forbion led Anaveon’s CHF 110 million Series B. Anaveon is developing engineered cytokine therapies for cancer, including programmes intended to activate anti-tumour immune responses in solid tumours.

Medicxi

European life-sciences investment firm focused on therapeutics and asset-centric biotechnology.

Stage
Seed · Series A · Growth
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

Medicxi was the founding investor in Ottimo Pharma and participated in its Series A of more than $140 million in December 2024. Ottimo is developing bifunctional antibody medicines for solid tumours, giving Medicxi a direct company-creation and oncology-financing precedent.

LifeArc Ventures

Venture arm of LifeArc investing in companies translating biomedical science into new treatments.

Stage
Seed · Series A · Series B
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

LifeArc Ventures is an existing investor in Cytospire Therapeutics and participated in its £61 million Series A in May 2026. Cytospire is developing gamma-delta T-cell engager antibodies for solid and haematological cancers.

Cambridge Innovation Capital

Cambridge-focused investor backing life sciences and deep technology from early stage onward.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Europe
Investor type
VC

Relevant investment

Cambridge Innovation Capital co-led T-Therapeutics’ £48 million Series A in 2023 and participated again as the round expanded to $91 million in 2025. T-Therapeutics develops next-generation T-cell-receptor bispecific medicines for cancer and autoimmune disease.

Criteria Bio Ventures

Specialist European life-sciences investor focused on biotechnology and therapeutics.

Stage
Seed · Series A
Sector / Focus
Oncology · Biotechnology · Therapeutics
Investment markets
Europe
Investor type
VC

Relevant investment

Criteria Bio Ventures participated in Cytospire Therapeutics’ £61 million Series A in May 2026. Cytospire is developing first-in-class pan-gamma-delta T-cell engagers for solid and blood cancers, giving Criteria a direct European oncology precedent.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.